Programs

Selectively Depleting Highly Cytotoxic Effector Memory CD8+ T cells for the Treatment of Autoimmune Diseases 

KLRG1 (Killer Cell Lectin-like Receptor G1) is specifically expressed on highly cytotoxic effector memory CD8+ T cells. These cells are responsible for tissue damage in several autoimmune and inflammatory diseases, and their selective depletion with an anti-KLRG1 antibody has the potential to achieve long lasting clinical benefits without global immune suppression. 

Our DIS^® Approach

HiFiBiO’s DIS®-driven single cell immune profiling data suggests that infiltration and expansion of KLRG1+ lymphocytes plays a role in a number of autoimmune and inflammatory diseases. Therefore, selective depletion of KLRG1+ T cells is an attractive approach for autoimmune disease treatment. 

Drug Info

HFB3024 is an anti-KLRG1 biparatopic antibody developed to deplete KLRG1+ cells via antibody dependent cellular cytotoxicity and phagocytosis. In preclinical studies, HFB3024 shows potent binding to human and cynomolgus KLRG1 and exhibits selective depletion of effector memory CD8+ T cells while sparing other T cell populations.